mRNA Therapeutics for Fabry Disease via Lipid Nanoparticle Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Fabry disease, including enzyme replacement therapy, are ineffective in maintaining physiological levels of α-galactosidase A (GLA) activity and reducing globotriaosylceramide (Gb3) accumulation, leading to progressive tissue damage and complications.
Innovation Solution
The development of mRNA therapeutics that encode GLA, utilizing modified nucleotides to minimize immune activation and optimize translation efficiency, delivered via lipid nanoparticles (LNPs) to achieve sustained GLA protein expression and reduced Gb3 levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If enzyme replacement therapy is used to treat Fabry disease, then some symptom relief may be achieved, but it is ineffective in maintaining physiological levels of GLA activity and reducing Gb3 accumulation
Solution Approach 1:
The patent changes the fundamental parameter of GLA delivery from exogenous enzyme replacement to endogenous protein synthesis via mRNA. By introducing mRNA encoding GLA into patient cells, the system enables continuous de novo synthesis of functional GLA protein, maintaining physiological levels of enzyme activity and effectively reducing Gb3 accumulation in lysosomes.
2Reliability
If modified nucleotides are incorporated into therapeutic mRNA, then immune activation is minimized and translation efficiency is optimized, but the complexity of mRNA synthesis increases
Solution Approach 1:
The patent applies local quality modifications by incorporating modified nucleotides at specific positions within the mRNA sequence. These modifications are strategically placed to minimize immune activation and optimize translation efficiency without requiring comprehensive modification of the entire mRNA molecule, thereby balancing performance improvement with synthesis feasibility.
3Duration of action of moving object
If lipid nanoparticles are used to deliver mRNA, then sustained GLA protein expression is achieved, but the complexity of the delivery system increases
Solution Approach 1:
The patent introduces lipid nanoparticles as an intermediary delivery vehicle that facilitates the introduction of mRNA into patient cells. These nanoparticles protect the mRNA from degradation, enable cellular uptake, and ensure sustained release of the therapeutic mRNA, thereby achieving prolonged GLA protein expression while managing delivery system complexity through a well-established nanotechnology platform.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The mRNA therapeutic approach effectively increases and maintains GLA activity in plasma and tissues for extended periods, significantly reducing Gb3 and lyso-Gb3 levels, thereby alleviating Fabry disease symptoms and slowing disease progression.
Implementation Method 1
delivered via lipid nanoparticles (LNPs) to achieve sustained GLA protein expression
Implementation Method 2
optimize the translation efficiency of mRNA to protein
Implementation Method 3
GLA, which is also referred to as GALA, is a homodimeric glycoprotein that hydrolyzes the terminal α-galactosyl moieties from glycolipids and glycoproteins
Data Source
AI summary
The invention relates to mRNA therapy for the treatment of Fabry disease. mRNAs for use in the invention, when administered in vivo, encode human the α-galactosidase A (GLA), isoforms thereof, functional fragments thereof, and fusion proteins comprising GLA. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of GLA expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient GLA activity in subjects, namely Gb3 and lyso-Gb3.